The Neuregulins and their receptors, the ErbB/HER subfamily of receptor tyrosine kinases, have critical roles in animal physiology, and their deregulation is frequent in cancer. Here we report the identification of the guanine nucleotide exchange factor, phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 (P-Rex1), as a novel mediator in signalling by ErbB/HER receptors. P-Rex1 was formerly described as a phosphoinositide 3-kinase and Gbc activated protein that regulates Rac function. We define how ErbB/HER receptors regulate P-Rex1 function, which involves dephosphorylation of inhibitory residues, and phosphorylation of activating residues of P-Rex. The net balance resulting from activation of this phosphorylation/dephosphorylation cycle of P-Rex1 favours Rac activation. Molecular and biological studies indicated that P-Rex1 phosphorylation regulated the proliferation of breast cancer cells, and P-Rex1 knockdown affected their migration or invasiveness, as well as their in vivo tumourigenic potential. Moreover, as we found correlation between high P-Rex1 expression and poor patient outcome in breast cancer, P-Rex1 targeting may be therapeutically relevant in cancer.
Introduction
The ErbB/HER subfamily of receptor tyrosine kinases (RTKs) includes four transmembrane tyrosine kinases termed epidermal growth factor receptor/ErbB1/HER1, ErbB2/neu/HER2, ErbB3/HER3 and ErbB4/HER4 (Hynes and Lane, 2005) . These receptors participate in important physiological processes, such as heart and nervous system development, and their increased activity accompanies several types of tumours. Thus, ErbB2/HER2 is frequently overexpressed in breast cancer (Slamon et al., 1989) , and agents that target this receptor, such as the monoclonal antibody trastuzumab or the small-molecule tyrosine kinase inhibitor lapatinib, are used to treat patients with ErbB2/HER2-positive tumours (Esteva et al., 2009) . Molecular alterations or overexpression of the epidermal growth factor receptor has been reported in lung, colon, head and neck cancer, and glioblastoma, and agents that target this receptor have also reached the oncology clinic (Baselga and Arteaga, 2005) .
In addition to overexpression or molecular alterations, ErbB/HER receptors may be activated by ligands of the epidermal growth factor family (Massague´and Pandiella, 1993) . The Neuregulins (NRGs) represent the largest subclass of polypeptide factors of this family of ligands (Montero et al., 2008) , and were initially isolated on the basis of their ability to cause ErbB2/HER2 activation (Holmes et al., 1992) . Later, several studies demonstrated that NRGs do not directly bind to ErbB2/ HER2, but rather cause its activation after binding to ErbB3/HER3 or ErbB4/HER4, which are able to form heteroligomeric complexes with ErbB2/HER2 (Carraway et al., 1994; Sliwkowski et al., 1994) . Increasing evidence indicates that NRGs may have a relevant role in cancer. Thus, expression of NRGs has been described in several tumour types (Breuleux, 2007; Montero et al., 2008) , and has been linked to the response to trastuzumab in breast cancer (Yuste et al., 2005; de Alava et al., 2007) . In addition, expression of transmembrane NRGs in breast cancer cells activates ErbB2/ HER2, and favours their proliferation in vitro (Yuste et al., 2005) . Moreover, expression of NRG in the mammary gland induces adenocarcinomas in animal models (Krane and Leder, 1996) , and favours metastatic spread of breast cancer cells (Atlas et al., 2003; Tsai et al., 2003) . In line with the latter, it has been shown that NRGs cause cytoskeletal reorganization that facilitates a motile phenotype (Adam et al., 1998) . Although the mechanisms by which such changes occur are largely undefined, some reports indicated that NRGs may affect the activity of Rac, a Rho family member that controls the actin cytoskeleton (Yang et al., 2006) . Moreover, Rac has been implicated in the mitogenic responses that follow ErbB receptor activation (Yang et al., 2008) . However, the mechanisms by which NRGs control Rac activity have not been elucidated.
Here, we show that NRGs control Rac activity in breast cancer cells by provoking changes in the phosphorylation of the Rac guanine nucleotide exchange factor phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 (P-Rex1). P-Rex1 was initially described as a Rac guanine nucleotide exchange factor, activated by the bg subunits of heterotrimeric G proteins, and by phosphatidylinositol (3,4,5)-trisphosphate, which is generated by phosphoinositide 3-kinase (Welch et al., 2002) . We demonstrate that stimulation of ErbB receptors by NRGs causes rapid activation of a phosphorylation/dephosphorylation cycle of P-Rex1 in which serines 313 and 319 are dephosphorylated, although phosphorylation at serines 605 and 1169 increases. Mutagenesis studies indicated that phosphorylation at Ser 313 and Ser 319 restrains Rac activity, whereas phosphorylation at Ser 605 and Ser 1169 favours Rac activity. Moreover, P-Rex1 phosphorylation regulated NRG-induced cell proliferation, and P-Rex1 knockdown decreased migration or invasiveness of breast cancer cells, as well as their in vivo tumourigenic potential. Finally, we report that the expression of P-Rex correlates with the aggressive behaviour of human breast cancers. Therefore, P-Rex may act as a novel and important signal transducer of pro-oncogenic signals that emanate from receptor tyrosine kinases, and should be considered as a potential therapeutic target.
Results

NRG provokes phosphorylation of a 180-kDa protein
The role of the NRG-ErbB signalling axis in mammalian biology and its relevance in the pathophysiology of several types of solid tumours have stimulated much research to describe signalling networks that participate in the actions of this ligand-receptor system. We previously reported the identification of the extracellular signal-regulated kinase 5 pathway as part of the NRGErbB signalling axis in breast cancer cells (EsparisOgando et al., 2002) . Along additional studies to define the importance of other pathways in NRG-ErbB signalling, we observed that an antibody that we generated against Akt phosphorylated at the Ser 473 position also recognized a band doublet with an M r substantially higher than Akt in MCF7 breast cancer cells treated with NRG ( Figure 1a ). For simplicity, we will refer to that band doublet as p180. Obvious candidates were the ErbB receptors, because of their molecular weight and preferential phosphorylation upon interaction with NRG. However, cell fractionation experiments indicated that p180 was cytosolic (Figure 1b) , supporting that it is not related to ErbB receptors. The above results indicated that NRG triggered phosphorylation of a cytosolic 180-kDa protein, which likely represented an unknown intermediate in NRG signalling.
Identification of p180 as P-Rex1
To identify the p180 protein, we used a strategy initiated with a prepurification step, based on the fact that p180 was a cytosolic protein. Control and NRG-treated MCF7 cells were homogenized and the cytosolic fraction was passed along a column that contained a matrix for the purification of phosphorylated proteins. The eluates were run on large sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE) gels, which were silver-stained. The 180-kDa region (Figure 1c ) was excised and subjected to mass spectrometry analysis (Figure 1d ). Three proteins were identified using this approach, namely P-Rex, JIP4 and the ubiquitin-conjugating enzyme E20. Of these proteins, we considered P-Rex as the most likely candidate to be p180, as (i) most of the peptides identified in the mass spectrometry analyses corresponded to P-Rex (Figure 1d , and Supplementary Table 1); and (ii) an anti-P-Rex antibody recognized a band doublet in MCF7 cells that migrated with the same M r as the p180 band (Figure 1e ). In addition, P-Rex has also been reported to migrate in SDS-PAGE gels as a band doublet (Mayeenuddin and Garrison, 2006) . For these reasons, we selected P-Rex to further investigate whether this protein corresponded to p180. P-Rex includes several different isoforms originated from two distinct P-REX genes (Welch et al., 2002; Donald et al., 2004; Rosenfeldt et al., 2004 , and the Genecards-Ensemble database). The P-REX1 gene codes for three different isoforms of 1659, 1562 and 956 amino acids, and the isoforms from the P-REX2 gene include proteins of 1606, 1504 and 979 amino acids ( Figure 2a) . We analyzed the presence of P-Rex1 and P-Rex2 in different breast cancer cell lines by reverse transcription-PCR, firstly using primers that do not discriminate between the distinct isoforms. These experiments indicated that P-Rex2 was undetectable in the breast cancer cell lines analyzed (Figure 2b ). However, in the neuroblastoma cell line SH5Y, which was used as a control, P-Rex2 was detected (data not shown). Additional reverse transcription-PCR experiments with isoform-specific primers indicated that isoforms 1 and 3 of P-Rex1 were present in MCF7 cells ( Figure 2c ). As the expected M r of isoform 2 of P-Rex1 was incompatible with the M r of p180, and was not expressed in MCF7 cells, this isoform was excluded from further analyses.
To study the expression of isoforms 1 and 3 of P-Rex1, we raised several antibodies. It should be noted that the antibody available for the experiment shown in Figure 1e was unable to precipitate P-Rex, and did not distinguish between distinct P-Rex1 isoforms (data not shown, and Supplementary Figure S1A) . A fusion protein corresponding to amino acids 1032-1142 of P-Rex, as well as peptides corresponding to the Cterminus of P-Rex1 isoform 1 and isoform 3, was used to generate those antibodies (Supplementary Figure  S1A) . The serum raised against amino acids 1032-1142, named anti-pan-P-Rex, which is expected to recognize all P-Rex forms, immunoprecipitated P-Rex from MCF7 cells (Figure 2d ). In addition, the antibodies raised to the P-Rex1 isoform 1 and isoform 3 also precipitated a 180-kDa protein. The expression of both isoforms in MCF7 cells was also confirmed by western blotting with the isoform-specific antibodies (Figure 2e ). That the precipitated bands were specific was verified by competition experiments with the antigens against which the antibodies were raised (Supplementary Figure S1B) . Immunoprecipitation and western blotting analyses using the P-Rex1 antibodies showed expression of PRex1 in different breast cancer cell lines (Figure 2f) . Immunofluorescence experiments indicated a predominant cytosolic location of P-Rex in MCF7 cells (Supplementary Figure S1C) .
As we initially identified p180 based on its ability to be recognized by the anti-pS 473 -Akt antibody, to confirm that in fact P-Rex could be the anti-pS 473 -Akt crossreactive band, we stimulated MCF7 cells with NRG, and subjected anti-pan-P-Rex immunoprecipitates to western blotting with the anti-pS 473 -Akt antibody. The anti-pan-P-Rex immunoprecipitates offered the same migration and pattern as the p180 protein doublet recognized in whole-cell extracts by the anti-pS 473 -Akt antibody (Figure 2g ). Together, these results indicated that p180 corresponded to P-Rex1.
Multisite phosphorylation of P-Rex1 is controlled by receptor tyrosine kinases Interestingly, the anti-pS 473 -Akt antibody also recognized P-Rex in unstimulated cells, suggesting that a certain degree of resting P-Rex1 phosphorylation was present ( Figure 2g and Supplementary Figure S2A) . In fact, immunoprecipitation of P-Rex1, followed by phosphatase treatment, indicated that P-Rex1 was phosphorylated not only after treatment with NRG, but also under resting conditions (Figure 3a) . Treatment with the phosphatase resulted in a faster migration of P-Rex1 and compactation of the band doublet into an apparently unique band. Immunoprecipitation of P-Rex1 followed by western blotting with antibodies to p-Tyr, p-Ser and p-Thr indicated that P-Rex1 was recognized by the anti-pSer antibodies, and that this reactivity was present not only in P-Rex1 from NRG-treated cells but also in P-Rex1 from untreated MCF7 cells (Supplementary Figure S2A) . In vitro Control and NRGtreated MCF7 cells were homogenized and the cytosolic fractions was obtained. Cytosolic phosphoproteins were purified and ran on large SDS-PAGE gels, which were silver-stained (c). The 180 kDa region was excised and subjected to mass spectrometry analysis. The arrows in (d) indicate the mass of peptides corresponding to P-Rex (see also Supplementary Table 1) . (e) The p180 protein has an electrophoretic migration analogous to P-Rex. Cell extracts from MCF7 cell stimulated with or without NRG were analyzed with antipS 473 -Akt or anti-P-Rex (generously provided by Dr Mikio Hoshino) antibodies.
dephosphorylation experiments confirmed that P-Rex1 was serine phosphorylated (Figure 3b ). Noteworthy, we did not observe a major increase in P-Rex1 serine phosphorylation upon NRG treatment (Supplementary Figure S2A ). This fact was initially surprising, as it was difficult to reconcile with the increased signal obtained from P-Rex1 using the anti-pS 473 -Akt antibody in NRG stimulated cells.
To identify the P-Rex1 phosphorylated site(s), affinity-purified P-Rex was subjected to MS analyses. These studies identified four major regions of P-Rex1 phosphorylation that included potential phosphorylation sites at Ser (Figure 3c ), which were highly conserved in mammals (Supplementary Figure S2B ). We raised P-Rex1 phosphospecific antibodies using phosphopeptides corresponding to these regions (Figure 3d ) to analyze whether in fact P-Rex1 was phosphorylated at these sites and to investigate whether NRG affected these putative phosphorylations. In the case of Ser 605/606 , we decided to generate antibodies against the first of the serines, as the second serine was not conserved in dogs (Supplementary Figure S2B) . As shown in Figure 3e Akt antibody (Figure 3d ). The specificity of the anti-pS 1169 was confirmed by the failure of the antibody to recognize a Ser 1169 to alanine change in a myc-tagged version of P-Rex1 (Figure 3f) . Transfection of the complementary DNA coding for a myc-tagged form of human P-Rex1 into the HCC3153 breast cancer cell line, on which endogenous P-Rex1 expression was low, confirmed that NRG was able to increase P-Rex1 phosphorylation at Ser 1169 ( Figure 3g ). Noteworthy, the mere expression of P-Rex1 provoked a small degree of resting phosphorylation, in agreement with the results also observed in MCF7 cells. In addtion, we were able to detect pS 1169 -P-Rex in primary breast cancer cells harvested from the ascites fluid of a patient with breast cancer, and the amount of pS 1169 -P-Rex was upregulated by treatment with NRG ( Figure 3h ). Therefore, NRG appears to activate a phosphorylation/dephosphorylation cycle of P-Rex1 in breast cancer cells that results in , anti-p-S 605 , anti-p-S 1169 ). (f) Specificity of the anti-p-S 1169 antibody of P-Rex1. MCF7 cells transfected with myc-tagged wild type P-Rex1 or P-Rex1 mutated in serine 1169 to alanine, were treated with NRG. Cell extracts were immunoprecipitated with the anti-myc antibody and the blot was probed with the anti-p-S 1169 antibody. This blot was reprobed with the anti-pan-P-Rex antibody that was used as a transfection control. (g) Where indicated, myc-P-Rex1 was transfected into HCC3153 cells, and the cells were treated with or without NRG. The cell lysates were immunoprecipitated with anti-pan-P-Rex and the blot was probed with the anti-p-S 1169 (top panel) or with the anti-pan-P-Rex (bottom panel). (h) Breast cancer cells obtained from the ascites fluid of a patient were stimulated with or without NRG and lysed. The cell extracts were separated by SDS-PAGE and blots were probed with the anti-p-S 1169 (top panel) or the anti-pan-P-Rex (bottom panel) antibodies. (i) MCF7 and T47D cells were treated during 15 min with different ligands of RTKs: NRG, insulin-like growth factor-I (IGF-I), epidermal growth factor (EGF) (all at 10 nM) or (j) HS578T cells were treated with or without 10 nM PDGFBB. After immunoprecipitation of P-Rex, its phosphorylation at S 1169 was analyzed as above. . We next analyzed whether P-Rex1 phosphorylation could also be triggered by other RTKs. MCF7 and T47D breast cancer cells were treated with a number of ligands known to activate distinct RTKs, and the phosphorylation of P-Rex1 analyzed with the antipS 1169 -P-Rex1 antibody. As shown in Figure 3i , treatment with NRG also increased pS 1169 -P-Rex1 in T47D cells. Insulin-like growth factor-I induced clear phosphorylation of P-Rex1 at Ser 1169 in both MCF7 and T47D breast cancer cell lines. In addition, PDGF-BB also provoked an increase in pS 1169 -P-Rex1 in the basal type breast cancer cell line HS578T (Figure 3j ). Together, these data indicated that regulation of the phosphorylation status of P-Rex1 could be a general phenomenon triggered upon activation of different RTKs.
Opposing effects on Rac activity of the distinct P-Rex1 phosphorylation sites We next explored to which extent P-Rex1 phosphorylation could regulate its function. As a first step, we evaluated whether P-Rex1 had a role in the regulation of Rac activity upon stimulation of NRG receptors. To this end, we created several clones of MCF7 cells on which P-Rex1 expression was downregulated by using two distinct short hairpin RNA interference sequences ( Figure 4a , and Supplementary Figure S3A ). NRG increased Rac activity in all the different clones tested (Figure 4b ). However, the fold increase in Rac activity caused by NRG in wild-type MCF7 cells was higher than the increase observed in the clones of MCF7 cells in which P-Rex1 amounts were substantially decreased. The mean percentage increase in Rac activity in cells treated with NRG with respect to the untreated controls was 33% in the case of wild-type MCF7, versus 22% in clone 4 and 13% in clone 5. Of note, resting Rac activity was significantly lower in the interfered clones. Moreover, expression of P-Rex1 in the HCC3153 cell line resulted in an increase in both resting and especially NRG-stimulated Rac activity (Supplementary Figure  S3B) . That the decreased action of NRG on Rac activity in the P-Rex1 interfered clones was not due to a decrease in the activation of ErbB receptors was evidenced by the identical activation of the receptors and Akt upon NRG treatment (Supplementary Figure S3C) .
Having performed these experiments, which demonstrated that P-Rex1 acted as a mediator regulating Rac activation in response to NRG, we then explored the importance of the distinct P-Rex1 phosphorylation sites in such a regulation. First, the kinetics of phosphorylation of the different sites in response to NRG was analyzed, and we also measured in parallel the action of NRG on Rac activity (Figures 4c and d) . These kinetic studies confirmed that NRG decreased serine phosphorylation at Ser 313 and Ser 319 sites and increased serine phosphorylation at Ser 605 and Ser 1169 sites. The kinetics of the changes in the phosphorylation status of these latter residues was similar to the kinetics of Rac activation (Figure 4d ).
The fact that serine phosphorylation at several sites was inversely regulated by NRG opened the possibility that activation of Rac by NRG could be facilitated by this phospho/dephosphorylation cycle, in which Ser 313 and Ser 319 sites could be restraining, whereas Ser 605 and Ser 1169 sites could facilitate P-Rex1 activity. To test this possibility, we created mutants of P-Rex1 at these individual sites. MCF7 cells were transfected with these myc-tagged mutant forms, created by point mutations of the individual serines to alanines. Expression of the PRex1-Ser 313 -Ala resulted in increased resting Rac activity. Although the increase in Rac activity by NRG was also higher than in cells transfected with myc-tagged wild-type P-Rex1, the relative increase in Rac activity was analogous (Figure 4e) . Transfection of the P-Rex1-Ser 319 -Ala did not affect the action of NRG on Rac activation as much as the P-Rex1-Ser 313 -Ala mutant (data not shown). These data are in line with an inhibitory role of the serine phosphorylation of these sites on P-Rex1 functioning as a Rac guanine nucleotide exchange factor. In contrast, expression of the P-Rex1-Ser 1169 -Ala mutant decreased Rac activity upon NRG treatment (Figure 4e ). Together, these data indicate that P-Rex1 may nucleate stimulatory as well as inhibitory inputs on Rac activity through regulation of P-Rex1 phosphorylation at distinct sites.
P-Rex1 participates in multiple biological actions of NRG
The relevant role of Rac as a regulator of the cytoskeleton and the action of P-Rex1 on Rac activity in MCF7 cells raised the possibility that several biological actions of NRG on these cells could be mediated by P-Rex1. To investigate this, we explored various cellular properties related to the functioning of the cytoskeleton. For these experiments we used different P-Rex1 MCF7 clones selected using two distinct short hairpin RNA interference sequences (see above). The response to NRG of these clones was compared with that of wild-type and a controltransfected RNA interference sequence. In wound-healing assays, we observed that reduction of P-Rex1 strongly affected constitutive and NRG-stimulated motility of MCF7 cells (Figure 5a ). Invasion through matrigel was also compromised in MCF7 cells with lowered levels of P-Rex1 (Figure 5b) , as it showed adhesion to fibronectin (Figure 5c ). Together, these results indicate that P-Rex1 participated in multiple biological properties of MCF7 cells, and knockdown of P-Rex1 affected the response of these cells to NRG.
As one of the principal actions of NRG in breast cancer cells is the stimulation of cell proliferation, we decided to explore the potential participation of P-Rex1 in this response. Treatment with NRG increased MCF7 proliferation, as indicated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) metabolization experiments, and this effect was profoundly affected in P-Rex1-interfered clones (Figure 5d ). As we did not detect increased apoptosis in P-Rex1 knockdown cells, the lower MTT metabolization rates observed in these cells are expected to be caused by reduced proliferation. To explore to which extent phosphorylation of P-Rex1 at distinct sites was involved in proliferation responses to NRG, we expressed the P-Rex1-Ser 319 -Ala or the PRex1-Ser 1169 -Ala mutants in MCF7 cell clones on which P-Rex1 was knocked down. Even though these clones were generated by inserting short hairpin RNAs that decreased endogenous P-Rex1 expression, transfection of the myc tagged mutants was able to reconstitute expression of P-Rex1, likely because an excess of transfected P-Rex1 overcomes the dose of the P-Rex-1 short hairpin RNA (Figure 5e ). Expression of wild-type P-Rex1 increased the proliferative response to NRG, as compared with the proliferation of the P-Rex1-interfered clones (Figure 5e ). Transfection of P-Rex1-Ser 1169 -Ala was unable to rescue NRG-induced proliferation to levels analogous to those obtained by re-expression of wild-type P-Rex1. Interestingly, transfection of P-Rex1-Ser
313
-Ala slightly favoured proliferation with respect to wild-type-transfected P-Rex1. The effect of this mutant was more pronounced in HCC3153, the triple-negative-type cell line whose endogenous levels of P-Rex1 were low ( Figure 5f ).
P-Rex1 facilitates tumour progression in vivo
To examine the in vivo role of P-Rex1 in breast cancer, we used a xenograft model of MCF7 cells in nude mice, and analyzed the growth of tumours from wild-type and P-Rex1-interfered MCF7 cells. The growth of the tumours from P-Rex1 knockdown cells was restricted as compared with tumours from mice injected with MCF7 cells (Figure 6a ). Western blotting of excised tumour samples verified the decreased levels of P-Rex1 in samples obtained from tumours of MCF7 cells in which P-Rex1 was knocked down (Figure 6b ). , S 1169 ) phosphorylated in P-Rex corresponding to the experiment shown in c. Rac activation as assessed by Enzyme linked immunosorbent assay is plotted and represented as the mean ± s.d. of duplicates from an experiment that was repeated twice. (e) Opossing effect on Rac activity of the distinct P-Rex1 phosphorylation sites. MCF7 cells were transfected with myc-tagged wild type P-Rex1, or P-Rex1 mutated in serine 313 to alanine, or in serine 1169 to alanine. Where indicated, NRG was added for 15 min, and then cells were lysed. Rac activity was measured as described under experimental procedures. An aliquot of the extracts was immunoprecipitated with the anti-myc antibody and the blot was probed with the anti pan-P-Rex antibody. The graphics (b, e) represents the mean±s.d. of triplicates from an experiment that was repeated three times.
We also explored the presence of P-Rex in human breast tumours (n ¼ 40) and its potential relationship with clinical outcome. The higher expression of P-Rex was observed in samples BT55, BT207, BT573, BT618, BT1026 and BT1080, and mild, low or undetectable expression in the rest of the samples (Figure 6c) . None of these patients were HER2 positive. The breast tissue from two normal breasts did not contain detectable amounts of P-Rex. As the biochemical studies associated expression of P-Rex with an increase in (a-e) MCF7 cells transfected with vectors coding for the short hairpin against P-Rex (clone 4 and clone 5) or the sh-control were plated and treated with or without NRG 10 nM and (a) the motility was measured 2 days later, *Po0.05, **Po0.01 (Student's t-test), (b) the number of invading cells was measured 3 days later, **Po0.01 (Student's t-test), (c) the percentage of cell adhesion was measured 2 h later, **Po0.01 (Student's t-test), and (d) the MTT metabolization was measured 3 days later, **Po0.01 (Student's t-test). A representative image of adherent MCF7 cells, sh-control, clone 4, and clone 5 is shown at the left of panel c. (e) P-Rex-interfered MCF7 cells (clone 4) were transfected with wild type P-Rex1, or P-Rex1 mutated in serine 313 to alanine, or in serine 1169 to alanine. NRG was added to the cultures, where indicated. MTT metabolization was measured 3 day later. Western analyses of the expression of total P-Rex and myc-P-Rex were used to verify reconstitution of P-Rex. (f) HCC3153 cells transfected with wild type P-Rex1, or P-Rex1 mutated in serine 313 to alanine, or in serine 1169 to alanine were treated with or without NRG and MTT metabolization measured 3 day later. Expression of myc-P-Rex was used as transfection control. The graphics (a-f) represent the mean ± s.d. of quadruplicates from an experiment that was repeated three times.
proliferation, we analyzed whether tumours with high expression of P-Rex were associated with a more aggressive phenotype. For these studies, we used the clinical data from patients who had follow-ups of at least 5 years (n ¼ 36, see Supplementary Table 2) . No association was identified between P-Rex expression and clinical prognostic factors such as age, tumour size, nuclear grade, hormone receptor status or HER2/ErbB2 expression (Supplementary Table 3 and data not shown). Interestingly, Kaplan-Meier survival plots indicated that patients with tumours with higher expression of P-Rex had a shorter disease-free survival (DFS) compared with the rest of the patients (log rank 4.45; P ¼ 0.035) (Figure 6d ). Median DFS time was 14.13 months (95% confidence interval: 8.31-27.47) for patients with high levels compared with 34 months (95% confidence interval: 19.71-48.28) for those with lower levels. Furthermore, multivariate analyses for known prognostic factors in breast cancer showed that P-Rex was an independent marker (Supplementary Table 3 ). The association of high levels of P-Rex with poor outcome supports the oncogenic properties of P-Rex identified in the biochemical experiments.
Discussion
The present work identifies P-Rex as a mediator of several important biological responses triggered upon activation of ErbB receptors, and describes how these receptors control P-Rex function. The regulation of the function of P-Rex involved changes in its serine phosphorylation at different sites. Importantly, these changes in the serine phosphorylation status of P-Rex were not exclusively restricted to activation of ErbB receptors, but were also provoked by activation of other RTKs, such as the insulin-like growth factor-Ireceptor or the platelet-derived growth factor receptor (PDGFR). This indicates that the regulation of P-Rex phosphorylation may be an important event in the signalling upon activation of multiple RTKs.
The mechanism by which P-Rex function is regulated by activation of RTKs involves increased phosphorylation of certain sites (Ser 605 and Ser The tumours were dissected, homogenized, and lysed, and cleared extracts were used to evaluate expression of P-Rex by western blot. (c) Expression of P-Rex in the normal breast and in breast cancer samples from patients. The tumours were homogenized and lysed. A total of 1 mg of protein was immunoprecipitated with the anti-pan-P-Rex antibody and the blot was probed with the same antibody. Calnexin was used as a loading control. (d) Kaplan-Meier plots of DFS with respect to P-Rex levels. Patients with tumours with high expression of P-Rex (n ¼ 4) had a shorter DFS compared with the rest of the patients (mild and low), (n ¼ 32) (14.13 months (95% confidence interval: 8.31-27.47) for patients with high levels compared with 34 months (95% confidence interval: 19.71-48.28) for those with low levels). The difference was statistically significant in the log-rank test (P ¼ 0.035).
2005; Barber et al., 2007) . Interestingly, deletion of the PH domain results in a mutant that is 10 times more potent as a Rac exchanger than wild-type P-Rex (Hill et al., 2005) . Our results are also consistent with a regulatory function of the PH domain on P-Rex activity. Thus, mutation of Ser 313 and Ser 319 in P-Rex resulted in increased Rac exchange activity together with augmented proliferation under resting conditions and on NRG receptor activation. It is therefore possible that phosphorylation of these serines in the PH domain may keep P-Rex1 activity low, and their dephosphorylation may release an inhibitory constraint analogous to the effect that results from deletion of this domain of P-Rex.
Comparison of the Rac exchange activity of these phosphorylation mutants with that of PH-deleted P-Rex may define whether the PH domain contains additional Rac regulatory functions that do not depend on phosphorylation of Ser 313 and Ser
319
. The major serine phosphorylation site identified in our studies to be upregulated upon RTK activation was S 1169 . This site is included in the putative InsP4-phosphatase domain. Molecular characterization of PRex indicated that this region may keep the basal activity of P-Rex low, likely through an intramolecular interaction between the N-and C-terminal regions of PRex (Barber et al., 2007) . It is therefore possible that growth factor-mediated phosphorylation at this site may disrupt such interaction, releasing the inhibitory action that the InsP4-phosphatase domain exerts on the functionality of P-Rex towards Rac. It is also possible that this phosphorylation/dephosphorylation cycle may control the actions of P-Rex that are Rac-independent. In fact, in breast cancer cells interaction of P-Rex2a with phosphatase and tensin homolog inactivates the latter, causing activation of the phosphoinositide 3-kinase pathway without the apparent participation of Rac (Fine et al., 2009) . We have been unable to detect a significant amount of P-Rex2 in MCF7 cells, or an effect of P-Rex1 knockdown on Akt phosphorylation levels, either resting or NRG-stimulated. However, P-Rex1 knockdown substantially inhibited NRG-induced proliferation, adhesion, invasion and motility of MCF7 breast cancer cells. Moreover, studies in mice corroborated that P-Rex1 expression favoured growth of xenografted breast cancer cells. These preclinical data led us to analyze whether expression of P-Rex could be detected in breast cancer, and to explore any potential clinical link between P-Rex1 expression and patient outcome. These analyses indicated that P-Rex is expressed in a subset of breast cancer patients, and its expression negatively correlates with patient survival. In addition to our data, various other recent studies have implicated P-Rex in cancer. P-Rex2a levels are increased in some human cancers bearing wild-type phosphatase and tensin homolog and mutated PIK3CA, and provokes activation of the phosphoinositide 3-kinase route (Fine et al., 2009 ). In addition, increased expression of P-Rex1 in prostate cancer has been described, and its presence has been linked to Rac-mediated metastatic potential of prostate cancer cells (Qin et al., 2009 ).
Knockdown of P-Rex1 decreased NRG-induced Rac activity indicating that P-Rex1 participates in the control of Rac activity upon activation of NRG receptors. However, P-Rex1 knockdown only partially inhibited the ability of NRG to stimulate Rac activity. One possibility that may explain this is that the short hairpin RNA sequences used do not achieve complete knockout of P-Rex1 in MCF7 cells. Therefore, the remaining P-Rex could be responsible for the Rac activation upon stimulation of NRG receptors. Another possibility that should be contemplated is that stimulation of Rac activity by NRGs may also occur through alternative P-Rex1-independent pathways. Interestingly, the decrease in NRG-stimulated Rac activity in P-Rex1 knockdown cells was less pronounced than the effect of P-Rex1 knockdown on cell proliferation. These findings support the hypothesis that P-Rex1 may represent an important mediator in signalling proliferation through pathways that involve Rac-dependent as well as Rac-independent routes.
Our data identify P-Rex as a novel intermediate in mitogenic signalling by ErbB receptors, show the mechanism by which P-Rex is regulated by RTKs, and open new avenues of research in this field. Questions such as which kinases/phosphatases are involved in directing the phosphorylation-dephosphorylation cycle of P-Rex, as well as definition of the role of P-Rex in the actions of other cellular kinases, remain to be addressed. Also, additional studies to uncover the mechanisms by which P-Rex may promote cell proliferation or metastatic spreading have to be performed. Moreover, the association between high PRex expression and patient outcome in breast cancer points to P-Rex as a potential therapeutic target in tumours expressing elevated levels of P-Rex. Further studies in larger patient series and in other tumour types will help in defining the role of P-Rex in cancer.
Materials and methods
Reagents and immunochemicals
Geneticin (G418), culture medium and sera were purchased from Invitrogen (Gaithersburg, MD, USA). Protein ASepharose was from GE Healthcare Life Sciences (Piscataway, NJ, USA). Immobilon-P membranes were from Millipore Corp. (Bedford, MA, USA). Phosphatase l was from New England Biolabs (Ipswich, MA, USA). Mytomycin C, MTT, Fibronectin and puromycin were from Sigma Chemical (Madrid, Spain). NRG, epidermal growth factor and plateletderived growth factor-BB (PDGFBB) were from Prospec (Rehovot, Israel). Insulin-like growth factor-I was from Strathmann (Hamburg, Germany). Other generic chemicals were purchased from Sigma, or Merck (Darmstadt, Germany). Sequencing grade modified trypsin was from Promega (Madison, WI, USA). The anti-phosphotyrosine, anti-phosphothreonine and anti-glyceraldehyde 3-phosphate dehydrogenase were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The 4D5 anti-HER2/ErbB2 ectodomain antibody was provided by Dr Mark X Sliwkowski (Genentech, San Francisco, CA, USA). The anti-HER2 antibody (Ab3) used for western was from Calbiochem (La Jolla, CA, USA). The anti-HER3/ErbB3 antibody was generated against a glutathione S-transferase-HER3 fusion protein, and will be described elsewhere. The antiphosphoserine was from ZYMED Laboratories (San Francisco, CA, USA). The anti-calnexin antibody was from Stressgen Biotechnologies Corporation (Glanford Avenue, Canada). The anti-Myc antibody was from Sigma. A rat monoclonal anti-P-Rex antibody was provided by Dr Mikio Hoshino (Department of Pathology and Tumour Biology, Kyoto University Graduate School of Medicine, Japan). Horseradish peroxidase conjugates of anti-rabbit and anti-mouse IgG were from Bio-Rad Laboratories (Madrid, Spain). Anti-Rac was from Cytoskeleton (Denver, CO, USA). Anti-p-Y 877 -HER2 was from Cell Signalling.
Cell culture and transfections BT474, SKBR3, T47D, HCC3153, HS578T and MCF7 cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 mU/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine, in a 95:5 air-CO 2 atmosphere at 37 1C. Transfections of MCF7 and HCC3153 cells were performed with JetPEI DNA transfection reagent (Polyplus-transfection SA, Illkirch, France) following the manufacturer's instructions.
To generate MCF7 cell lines expressing low levels of P-Rex, cells were transfected using JetPEI with lentiviral vectors containing two different short hairpin P-Rex RNA-coding sequences (Sigma). To express exogenous P-Rex1 (isoform 1) into MCF7 or HCC3153, cells were transfected with pCMV3-myc-P-Rex1-1. Clones of MCF7 or HCC3153 were then selected with 3 mg/ml of puromycin or with G418 500 mg/ml, respectively, and the expression of P-Rex1-1 was analyzed by western blotting with anti-myc or anti-P-Rex antibodies.
Immunoprecipitation and western blotting Cells were washed with phosphate-buffered saline and lysed in ice-cold lysis buffer (140 mM NaCl, 10 mM ethylenediaminetetraacetic acid, 10% glycerol, 1% Nonidet P-40, 20 mM Tris, pH 7.0, 1 mM pepstatin, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mM phenylmethyl sulphonyl fluoride (PMSF), and 1 mM sodium orthovanadate). Samples were centrifuged at 10 000 g at 4 1C for 10 min, and supernatants were transferred to new tubes with the corresponding antibody and protein A-Sepharose. The rest of the immunoprecipitations and western blotting procedures were as described by Cabrera et al. (1996) .
Protein and phosphorylated peptides identification
To identify p180, NRG-treated MCF-7 cells were washed with phosphate-buffered saline and fractionated into microsomal and cytosolic fractions as described . The cytosolic fraction was loaded in a column (PhosphoCruz Protein Purification System, Santa Cruz Biotechnology) that contained a matrix for the purification of phosphorylated proteins. The eluates were concentrated and loaded in SDS-PAGE gels. Gels were silver stained and bands of interest were excised and digested with trypsin. The protein peptide mass fingerprint was obtained on an Ultraflex MALDI-TOF mass spectrometer (Bruker Daltonics, Brenen, Germany) and used to identify the proteins by MASCOT search against Swiss-Prot database.
For the identification of P-Rex phosphorylated amino acids, MCF-7 cells were stimulated with NRG for 10 min. Cell lysates were inmunoprecipitated with anti-pan-P-Rex. The samples were loaded in SDS-PAGE gels and the bands corresponding to P-Rex were visualized with silver stain and digested with trypsin. Phosphopeptides were enriched using TiO 2 microcolumns (Larsen et al., 2005) , and phosphopeptides were analyzed with an Ultraflex MALDI-TOF mass spectrometer and the Flexcontrol 3.0 software (Bruker Daltonics).
Reverse transcription-PCR assays
Messenger RNAs of the different cell lines were prepared using TRIZOL (Invitrogen Corp.) and complementary DNA synthesized. The complementary DNAs were used in PCR experiments with specific oligonucleotides designed to distinguish between the different P-Rex isoforms: P-Rex1 isoform 1:, forward 5 0 -CTGCCTTCTCCAGGCAG C-3 0 and reverse 5 0 -AATCTCCACCCTTGGGCC-3 0 . P-Rex1 isoform 2:, forward 5 0 -ATGGGGCTGGAGCAGATCAT-3 0 and reverse 5 0 -GAATGCACTGACCAGCAGAGA-3 0 . P-Rex1 isoform 3:, forward 5 0 -AAGGTGAGCTTCAGGCCTGG-3 0 and reverse 5 0 -TAGACCGCTCCAGGTAAAATG-3 0 . P-Rex2 (all isoforms):, forward 5 0 -GTGCAGACAAGGAAATCT G-3 0 and reverse 5 0 -GTCATGTTTCATAAGTCGATG-3 0 .
Generation of antibodies
For the generation of the anti-pan-P-Rex antibodies, rabbits were immunized with a glutathione S-transferase fusion protein that included amino acids 1032-1142 of P-Rex1. The antibodies recognizing isoform 1 or isoform 3 of P-Rex1 were raised against the sequences NH2-CRLYRLCQPPVDGDL-COOH and NH2-CSGLTCPRMPAPRR-COOH that correspond to the amino acids 1645-1659 of P-Rex1 isoform 1, and 1548-1561 of P-Rex1 isoform 3. For the generation of anti-phosphospecific antibodies of P-Rex1 and Akt, we immunized rabbits with the peptides: phosphoSer Cell proliferation, cell invasion, cell adhesion and wound-healing assays For cell proliferation assays, cells were plated in 24-well plates at 20 000 cells per well and cultured overnight in DMEM þ 10% fetal bovine serum. The next day (day 1 of culture) the medium was replaced with DMEM without fetal bovine serum, with or without NRG (10 nM). Cell proliferation was analyzed at 3 days by an MTT-based assay (Yuste et al., 2005) . Unless otherwise indicated, the results are presented as the mean ± s.d. of quadruplicates of a representative experiment that was repeated at least three times.
Cell invasion assays were performed at 37 1C using Transwells (BD Biosciences, San Jose, CA, USA) of polycarbonate with membrane inserts of 8.0 mm pores. A total of 12.5 mg of matrigel (BD Biosciences) in 100 ml of water was added to the bottom of each Transwell and once the matrigel had solidified, 10 5 cells (in 100 ml of DMEM with 1% fetal bovine serum, with or without 10 nM NRG) were seeded on the upper compartment of the chamber. After 3 days, the number of cells that migrated to the bottom of the chamber was stained with crystal violet and counted in a microscope. Three sets of experiments were carried out, each in triplicate.
To perform the wound-healing assay, cells were seeded in 60 mm plates and allowed to reach confluence. Wounding was created using plastic pipette tips, and the cells were serumstarved and treated with mitomycin C, and with or without NRG during 2 days. Images were captured in a microscope and the distance between the wound edges was measured using the ProgRes CapturePro 2.7 program (Jenoptik, Jena, Germany).
For the adhesion assays, the plates were pretrated with fibronectin overnight and 10 5 cells were seeded on the plates for 2 h. The dishes were then washed twice with phosphate buffered saline and stained with crystal violet.
Rac activity
Rac activity was evaluated using a G-LISA Rac activation assay Biochem Kit (Cytoskeleton, Denver, CO, USA) following the manufacturer's instructions. Rac exchange activity was also analyzed by Rac pulldown assays using the Rac binding domain of Pak (Supplementary Figure S4) .
Dephosphorylation assays
Extracts of MCF7 cells treated with or without NRG were inmunoprecipitated with anti-pan-P-Rex. The immunocomplexes were washed thrice with lysis buffer and twice with phosphatase buffer (0.1 mM ethylene glycol tetraacetic acid (EGTA), 100 mM NaCl, 0.01 Brij35, 50 mM Tris-HCl, pH 7.5) and then treated with or without 1 U of l phosphatase (New England Biolabs) at 30 1C during 2 h. The reactions were terminated by adding sample buffer, and the samples were analyzed by western blotting using anti-pan-P-Rex antibodies.
Plasmids
The pCMV3 plasmid containing wild type human P-Rex1 tagged with myc was provided by Dr Heidi CE Welch (Babraham Research Campus, Cambridge, UK). P-Rex1 phosphorylation mutants were generated by oligonucleotidedirected mutagenesis using the QuikChange kit (Stratagene, La Jolla, CA, USA) and following the manufacturer's instructions. The following oligonucleotides were used: P-Rex1-S313A forward:, 5 0 -CCGGGAGCAAGAAGGCC ACCAAGAGGACC-3 0 P-Rex1-S313A reverse:, 5 0 -GGTCCT CTTGGTGGCCTTCTTGCTCCCGG-3 0 P-Rex1-S319A,S323A forward:, 5 0 -CCAAGAGGACCAAAGCCATCAACGGCGC CCTCTACATCTTC-3 0 P-Rex1-S319A,S323A reverse:, 5 0 -GA AGATGTAGAGGGCGCCGTTGATGGCTTTGGTCCTC TTGG-3 0 P-Rex1-S605A,S606A forward:, 5 0 -GATGGAGGG GACCGCAGCAAAGAACAAACAGC-3 0 P-Rex1-S605A,S606A reverse:, 5 0 -GCTGTTTGTTCTTTGCTGCGGTCCCCTCC ATC-3 0 P-Rex1-S1169A,S1171N forward:, 5 0 -GAGTTATCG CGACGCCTACAACGAGTGTAACAGC-3 0 P-Rex1-S1169A, S1171N reverse:, 5 0 -GCTGTTACACTCGTTGTAGGCGTC GCGATAACTC-3
0
The glutathione S-transferase-P-Rex1 fusion protein used for the immunization of rabbits contained the amino acids 1032-1142 of P-Rex1, and was generated by PCR amplification with the oligonucleotides 5 0 -CGCGGATCCTGCTTGCC TGCTGCAGAG-3 0 (a BamHI site is underlined) and 5 0 -CCGCTCGAGTCACCCATGGTCACTCCTGTC-3 0 (an XhoI site is underlined).
Xenograft studies
Mice were manipulated at the animal facility following legal guidelines. Female BALBc nu/nu mice (7 weeks old) were obtained from Charles River Laboratories (Wilmington, MA, USA). A total of 5 Â 10 6 MCF7-short hairpin control (shcontrol), MCF7-sh-P-Rex1#4, or MCF7-sh-P-Rex1#5 cells in 100 ml of DMEM and 100 ml of Matrigel were injected into the mammary fat pad (n ¼ 7 animals for condition). Tumour diameters were serially measured with callipers every 4 days, and tumour volumes were calculated by the following formula: volume ¼ width 2 Â length/2. Tumour samples were obtained after killing the animals, and immediately frozen in liquid nitrogen. The tumours were minced, washed with phosphatebuffered saline, and homogenized (Dispomix, L&M Biotech, Holly Springs, NC, USA) in ice-cold lysis buffer (1.5 ml/ 100 mg of tumour). This homogenate was centrifuged at 10 000 g for 20 min at 4 1C, and the supernatants were transferred to new tubes. The expression of P-Rex was analyzed by western blot as above.
Patient samples P-Rex expression was evaluated by western in breast cancer samples from patients of the University Hospital of Salamanca. The frozen samples were randomly selected from patients that had undergone surgery during the 2004-2008 period. Processing of the frozen samples was performed essentially as described above for the excised tumour xenografts. Protein concentration was measured by the Bradford assay, and 1 mg was immunoprecipitated with the anti-pan-P-Rex antibody. After western blotting, the amount of P-Rex was quantitated using the NIH Image software (Research Services Branch, National Institutes of Mental Health, Bethesda, MD, USA), and subtracting the autoradiography background from each P-Rex band. Arbitrary unit values for the intensity of each band were obtained, and three groups of samples were established. Low or undetectable P-Rex expression was assigned to samples with intensity values between 0-10 arbitrary units. The two normal breast samples with values of 8.02 and 3.82 fell within this range. Intermediate expression was assigned to samples between 10-50 arbitrary units. High P-Rex expression values were assigned to samples with intensity values above 50 arbitrary units.
Statistical analyses
Comparison of continuous variables between two groups for in vitro assays and xenograft mice experiments were done using a two-tailed Student's t-test. Results were considered to be statistically significant when P-values below 0.05. Statistical data are presented as the mean ± s.d. or 95% confidence intervals. The number of experiments performed is indicated in the figure legend. DFS was calculated from the date of diagnosis to the date of recurrence or death. Kaplan-Meier survival analyses were carried out for DFS. Differences in DFS according to P-Rex expression were compared using the log-rank test. Multivariate analysis using the Cox proportional hazards models was performed to define prognostic independent factors for DFS. All statistical tests were conducted at a twosided significance level of 0.05, and were performed using the statistical software SPSS 15.0 (SPSS Inc, Chicago, IL, USA).
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